Halozyme Therapeutics (HALO) Tops Q3 EPS by 42c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $39.12 +0.38%
Revenue Growth %: +23.2%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
NLY, CP, RUSHA, More
Revenue Growth %: +23.2%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.74, $0.42 better than the analyst estimate of $0.32. Revenue for the quarter came in at $209 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of $661.33 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- O'Reilly Automotive (ORLY) Misses Q1 EPS by 7c, Offers Guidance
- First Bancorp. (FBNC) Misses Q1 EPS by 2c
- SLM (SLM) Tops Q1 EPS by 20c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
